ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
02-017
Phase 1 mab completed
Quick answer
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 for Leukemia is a Phase 1 program (mab) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Actinium Pharmaceuticals
- Indication
- Leukemia
- Phase
- Phase 1
- Modality
- mab
- Status
- completed